期刊文献+

山莨菪碱对多器官功能障碍综合征患者氧摄取的影响 被引量:9

Effect of anisodamine on the multiple organs dysfunction syndrome patients′ oxygen extraction
下载PDF
导出
摘要 目的 观察山莨菪碱对多脏器功能不全 (MODS)患者氧摄取的影响 ,并对其可能的机制进行探讨。方法  4 6例MODS患者随机分为A、B两组 ,B组行常规治疗 ,A组在常规治疗的基础上加用山莨菪碱 1mg·kg-1·d-1,观察治疗前及治疗第 1、2、3、5天两组患者氧摄取率的变化 ,同时观察两组升压药的使用情况及肺氧合指数的变化情况。结果 两组MODS患者治疗前氧摄取率均偏低 ,经治疗随病情改善氧摄取率提高 ,以A组更明显 (P <0 0 1) ,且A组患者的升压药使用量及时间均明显少于B组 (P <0 0 1) ,A组患者的肺氧合情况较B组改善更明显。结论 山莨菪碱能改善MODS患者的氧摄取 ,减少升压药的用量及使用时间 ,帮助提高肺氧合指数。 Objective To investigate the effect of anisodamine on the multiple organs dysfunction syndrome (MODS)patients′ oxygen extraction rate (OER), and at the same time try to find the probable mechanism.Methods 46 MODS patients were arranged at random to receive either standard treatment or adding anisodamine 1 mg·kg -1 ·d -1 .At the 0 and 1,2,3,5 days,we measured the OER of different groups,and the total quantity and time of vasoactive drugs used, and also calculated the oxygen index of the lung of patients at different time.Results Before treatment the oxygen extraction rate of all the MODS patients in two groups were low, after treatment OER of two groups got higher,and the anisodamine group changed more obviously (P<005).When treated with anisodamine, patients used fewer quantity of vasoactive drugs and the time was short.After treatment the oxygen index of all the two group patients were improved,and the anisodamine group was more obvious(P<001).Conclusion Anisodamine can help to improve the OER of MODS patients,and decrease the quantity and time of the vasoactive drugs used, at the same time improve the oxygen index of the lung.
出处 《中国急救医学》 CAS CSCD 北大核心 2004年第9期666-667,共2页 Chinese Journal of Critical Care Medicine
关键词 山莨菪碱 MODS 氧摄取率 肺氧合指数 Anisodamine MODS Oxygen extraction rate Oxygen index of lung
  • 相关文献

参考文献10

二级参考文献21

  • 1孙耕耘,毛宝龄.急性呼吸窘迫综合征的研究进展(现代呼吸系疾病系统讲座第十一讲)[J].中华结核和呼吸杂志,1996,19(4):196-198. 被引量:60
  • 2邱海波,杜斌,陈德昌,刘大为,马遂.危重病患者全身性炎症反应综合征的临床分析[J].中华医学杂志,1997,77(3):234-235. 被引量:16
  • 3苏静怡.山莨菪碱(654-2)抗休克作用机制的研究进展[J].生理科学进展,1985,16(5):317-317.
  • 4[1]Loskutoff DJ. Regulation of PAI-1 gene expression [J]. Fibrinolysis, 1991,5: 197-202
  • 5[2]Held C, Hjemdahl P, Rehnqvist N, et al. Fibrinolytic variables and cardiovascular prognosis in patients with stable angina pectoris treated with verapamil or metroprolol:results from the angina prognosis study in Stockholm [J]. Circulation, 1997, 95: 2 380-386
  • 6[3]Iwai N, Shimoike H, Nakamura Y, et al. The 4G/5G polymorphism of the plasminogen activator inhibitor gene is associated with the time course of progression to acute coronary syndromes [J]. Atherosclerosis, 1998, 136: 109-114
  • 7[6]Schneiderman J, Sawdey MS, Keeton MR, et al. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries [J]. Proc Natl Acad Sci USA, 1992, 89: 6 998-7 002
  • 8[7]Kohler HP, Grant PJ.Mechanisms of disease: plasminogen-activator inhibitor type 1 and coronary artery disease [J]. N Engl J Med, 2000, 342: 1 792-801
  • 9[8]Collins T.Endothelial nuclear factor-kappa B and the initiation of the atherosclerotic lesion [J]. Lab Invest, 1993, 68: 499-508
  • 10Yao Ym, Redl H, Bahrami S, et al. The inflammatory basis of trauma/shock- associated multiple organ failure. Intlamm Res, 1998, 47:201 - 210.

共引文献184

同被引文献121

引证文献9

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部